Company profile

Robert F. Friel
Incorporated in
Fiscal year end
Former names
Eg&g Inc
IRS number

PKI stock data



7 May 19
15 Jul 19
2 Jan 20


Company financial data Financial data

Quarter (USD) Mar 19 Dec 18 Sep 18 Jul 18
Revenue 648.74M 756.35M 674.31M 703.36M
Net income 35.41M 71.29M 76.55M 64.06M
Diluted EPS 0.32 0.64 0.69 0.57
Net profit margin 5.46% 9.43% 11.35% 9.11%
Operating income 53.33M 115.68M 80.2M 88.06M
Net change in cash -28.86M 13.6M -13.88M -17.41M
Cash on hand 134.25M 163.11M 149.51M 163.39M
Cost of revenue 340.93M 341.99M 363.22M
Annual (USD) Dec 18 Dec 17 Jan 17 Dec 14
Revenue 2.78B 2.26B 2.12B 2.24B
Net income 237.93M 292.63M 234.3M 157.78M
Diluted EPS 2.13 2.64 2.12 1.39
Net profit margin 8.56% 12.97% 11.08% 7.05%
Operating income 323.88M 295.62M 294.58M 165.01M
Net change in cash -39.02M -157.13M 184.44M
Cash on hand 163.11M 202.13M 359.27M 174.82M
Cost of revenue 1.44B 475.27M 437.36M 427.27M

Financial data from company earnings reports

Financial report summary

  • If the markets into which we sell our products decline or do not grow as anticipated due to a decline in general economic conditions, or there are uncertainties surrounding the approval of government or industrial funding proposals, or there are unfavorable changes in government regulations, we may see an adverse effect on the results of our business operations.
  • Our growth is subject to global economic and political conditions, and operational disruptions at our facilities.
  • If we do not introduce new products in a timely manner, we may lose market share and be unable to achieve revenue growth targets.
  • We may not be able to successfully execute acquisitions or divestitures, license technologies, integrate acquired businesses or licensed technologies into our existing businesses, or make acquired businesses or licensed technologies profitable.
  • We may not be successful in adequately protecting our intellectual property.
  • If we are unable to renew our licenses or otherwise lose our licensed rights, we may have to stop selling products or we may lose competitive advantage.
  • If we do not compete effectively, our business will be harmed.
  • Our quarterly operating results could be subject to significant fluctuation, and we may not be able to adjust our operations to effectively address changes we do not anticipate, which could increase the volatility of our stock price and potentially cause losses to our shareholders.
  • A significant disruption in third-party package delivery and import/export services, or significant increases in prices for those services, could interfere with our ability to ship products, increase our costs and lower our profitability.
  • Disruptions in the supply of raw materials, certain key components and other goods from our limited or single source suppliers could have an adverse effect on the results of our business operations, and could damage our relationships with customers.
  • The manufacture and sale of products and services may expose us to product and other liability claims for which we could have substantial liability.
  • If we fail to maintain satisfactory compliance with the regulations of the United States Food and Drug Administration and other governmental agencies in the United States and abroad, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil, criminal or monetary penalties.
  • Changes in governmental regulations may reduce demand for our products or increase our expenses.
  • The healthcare industry is highly regulated and if we fail to comply with its extensive system of laws and regulations, we could suffer fines and penalties or be required to make significant changes to our operations which could have a significant adverse effect on the results of our business operations.
  • Economic, political and other risks associated with foreign operations could adversely affect our international sales and profitability.
  • If we do not retain our key personnel, our ability to execute our business strategy will be limited.
  • If we experience a significant disruption in, or breach in security of, our information technology systems or those of our customers, suppliers or other third parties, or cybercrime, resulting in inappropriate access to or inadvertent transfer of information or assets, or if we fail to implement new systems, software and technologies successfully, our business could be adversely affected.
  • We have a substantial amount of outstanding debt, which could impact our ability to obtain future financing and limit our ability to make other expenditures in the conduct of our business.
  • Restrictions in our senior unsecured revolving credit facility and other debt instruments may limit our activities.
  • Our share price will fluctuate.
Management Discussion
  • This quarterly report on Form 10-Q, including the following management’s discussion and analysis, contains forward-looking information that you should read in conjunction with the condensed consolidated financial statements and notes to the condensed consolidated financial statements that we have included elsewhere in this report. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “plans,” “anticipates,” “intends,” “expects,” “will” and similar expressions are intended to identify forward-looking statements. Our actual results may differ materially from the plans, intentions or expectations we disclose in the forward-looking statements we make. We have included important factors below under the heading “Risk Factors” in Part II, Item 1A. that we believe could cause actual results to differ materially from the forward-looking statements we make. We are not obligated to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Content analysis ?
H.S. sophomore Avg
New words: amortizable, automated, biotech, Chinese, Cisbio, Codolet, commenced, coupon, cybercrime, derecognized, Error, explicitly, France, genomic, grew, identical, implicit, lessee, lessor, pharma, predominant, principle, ROU, SAS, seasonal, short, stronger, Yuan
Removed: acceptance, AG, agent, allergy, amortize, amounting, antidilution, approximated, assessed, Assignment, Assumption, assured, autoimmune, BEAT, billable, blood, British, bundle, bundled, buyer, cancel, capable, capitalization, capitalize, charge, charged, choice, choose, Clarifying, classify, closing, closure, Code, collectability, complex, complexity, concentrated, concurrent, configuration, considerable, consulting, consumption, contemplation, context, cord, Corporation, creation, DAS, dated, decided, decision, deductibility, deduction, defective, defer, delivered, depicting, detection, directly, disaggregate, disease, disposed, disregard, distinct, distributor, divestiture, element, eligible, enacted, entering, entitled, erosion, evidence, exceeded, exclude, exist, expanding, expansion, expectancy, explain, extended, facilitate, factor, FDII, fee, field, forma, fulfillment, functional, functionality, geographic, GILTI, good, granting, group, hand, hosted, identifying, imaging, imposed, Improving, India, Interpretive, invoice, invoiced, invoicing, IP, Japanese, laboratory, Labordiagnostika, Lastly, law, leader, legislation, line, list, lowering, maintenance, Medical, Medizinische, missing, modification, notice, objective, operation, output, ownership, participant, penalty, perfunctory, perpetual, persuasive, point, possession, practice, predictable, predominantly, prepaid, President, pro, processing, prohibition, promise, promised, provisional, purport, ratably, reagent, receive, recognizing, reconciling, recoverable, recovered, refine, reform, refundable, relation, Release, remeasured, repeal, replace, return, satisfaction, screen, separated, simplified, simplify, Social, solution, space, sponsored, stating, storage, stringent, subscribe, subscription, substantive, summarize, surrender, Suzhou, symbolic, taxable, territorial, title, training, transitional, treat, treatment, type, typical, unaudited, undelivered, upfront, utilization, Varex, Varian, VSOE, withdrawal, Yen